Indices pare all early gains; metal shares rally for 2nd day

Image
Last Updated : May 03 2024 | 10:50 AM IST
The Indian equity indices pared all early gains and traded in negative terrain with minor losses in morning trade. The Nifty traded below the 22,650 mark. Metal shares witnessed buying demand for the second consecutive trading session.

At 10:28 IST, the barometer index, the S&P BSE Sensex, declined 152.31 points or 0.21% to 74,465.75. The Nifty 50 index fell 18 points or 0.08% to 22,630.20.

In the broader market, the S&P BSE Mid-Cap index rose 0.43% and the S&P BSE Small-Cap index added 0.01%.

The market breadth was negative. On the BSE, 1,742 shares rose and 1,729 shares fell. A total of 183 shares were unchanged.

Earinngs Today:

Titan Company (up 0.03%), Britannia Industries(down 0.43%), Adani Green Energy(up 0.36%), Godrej Properties(up 0.09%), MRF( down 2.87%), Mahgalore Refinery and Petrochemicals(down 0.49%), Carborundum Universal(down 2.90%), Inox Wind(down 0.64%), Aptus Value Housing Finance(down 0.48%), First Source Solutions(up 0.19%), Raymond (down 2.63%), Go Fashions(India) (up 0.19%), Aarti Drugs(down 0.13%), Tatva Chintam Pharma Chemical (up .65%) will declare their Q4 earnings today.

Buzzing Index:

The Nifty Metal index advanced 1.07% to 9,373.95. The index jumped 2.16% in the two consecutive trading sessions.

Hindustan Zinc (up 7.13%), Vedanta (up 2.18%), Steel Authority of India (up 1.99%), NMDC (up 1.76%) and Tata Steel (up 1.58%) were the top gainers.

Among the other gainers were Jindal Steel & Power (up 1.5%), JSW Steel (up 1.16%), Hindalco Industries (up 1.08%), Welspun Corp (up 1.02%) and APL Apollo Tubes (up 0.8%).

Stocks in Spotlight:

CIE Automotive India shed 0.02%. The companys consolidated net profit declined 17.42% to Rs 231 crore on 0.55% fall in revenue to Rs 2,427 crore in Q4 FY24 over Q4 FY23.

Ajanta Pharma rallied 8.86% after the pharmaceutical company reported 65.82% jump in consolidated net profit to Rs 203 crore in Q4 FY24 as compared with Rs 122 crore in Q4 FY23. Revenue increased 19.53% YoY to Rs 1,054.08 crore in Q4 FY24.

Astec Lifesciences jumped 2.69%. The company reported consolidated net loss of Rs 0.96 crore in Q4 FY24 as compared with net loss of Rs 4.97 crore in Q4 FY23. Revenue jumped 21.08% YoY to Rs 154 crore in Q4 FY24.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 03 2024 | 10:36 AM IST

Next Story